Cervical cancer prevention: Feasibility of self-sampling and HPV testing in rural and urban areas of Bolivia: An observational study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2024
2024
Historique:
received:
30
05
2022
accepted:
25
09
2023
medline:
11
3
2024
pubmed:
7
3
2024
entrez:
7
3
2024
Statut:
epublish
Résumé
Cervical cancer is a major health problem in Latin America. In 2019, the Italian Agency for Development Cooperation (La Paz regional site) conducted a pilot study to estimate the prevalence of high-risk human papillomavirus (HPV) and the feasibility of HPV screening in Bolivia through self-sampling and portable and transportable laboratory instruments for HPV testing in urban and rural areas. Women aged 20-65 years from La Paz (urban area), Toro Toro (rural area), and Acasio (rural area) were enrolled in local public health centers between Dec 1, 2019, and June 30, 2021. Self-sampling was carried out with the Viba-Brush system (Rovers, Oss, Netherlands) and samples were preserved in ThinPrep containers (Hologic Corporation, San Diego, CA, USA). The GeneXpert system (Cepheid, Sunnyvale, CA, USA) for high-risk HPV testing detects HPV E6 and E7 DNA via real-time PCR in a mobile system of easy execution requiring minimal manual intervention. The system provides results in about 1 h. The hr- HPV prevalence data, overall and partial genotyping, were analyzed considering the following age groups: 20-34, 35-44, and 45-65 years old. 2168 women were enrolled: 614 (28.3%) in La Paz, 743 (34.3%) in Toro Toro, and 811 (37.4%) in Acasio. Only one sample was collected from each participant. 2043 (94.2%) of 2168 samples were adequate for HPV testing. 255 (12.5%) samples were positive for high-risk HPV. Comparing the urban area (La Paz) versus rural combined areas (Acasio+Toro Toro), using a logistic model, the HPV total rate was statistically significantly higher in the city of La Paz (15.0% vs 11.4%; OR:1.37;95% CI: 1.04-1.80). Furthermore, the HPV prevalence was declining by age, and the urban/rural odds ratio was 1.50; (95% IC 1.13-19). The overall HPV 16 positivity was 2.7% (55/2043) and for HPV 18/45 was 1.8% (37/2043) without any statistically significant differences between the three BHU enrolling centers. Only the prevalence of HPV group '39/56/66/68' was significantly higher in La Paz (p<0,001) in comparison to Acasio and Toro Toro. The total and age-adjusted prevalence of high-risk HPV infection in rural and urban areas in Bolivia, as measured with a validated test for screening, is similar to that observed in Europe and the USA. Our study shows that a screening protocol for HPV testing with self-sampling would be feasible in urban and rural areas in Bolivia, and that the reported high occurrence of cervical cancer in Bolivia is not related to a higher rate of high-risk HPV infections. Carrying out HPV tests locally avoids the issues associated with transportation and storage of the collected material and allows the participant to wait in the clinic for the test result, overcoming the very long response time for screening test in Bolivia.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical cancer is a major health problem in Latin America. In 2019, the Italian Agency for Development Cooperation (La Paz regional site) conducted a pilot study to estimate the prevalence of high-risk human papillomavirus (HPV) and the feasibility of HPV screening in Bolivia through self-sampling and portable and transportable laboratory instruments for HPV testing in urban and rural areas.
METHODS
METHODS
Women aged 20-65 years from La Paz (urban area), Toro Toro (rural area), and Acasio (rural area) were enrolled in local public health centers between Dec 1, 2019, and June 30, 2021. Self-sampling was carried out with the Viba-Brush system (Rovers, Oss, Netherlands) and samples were preserved in ThinPrep containers (Hologic Corporation, San Diego, CA, USA). The GeneXpert system (Cepheid, Sunnyvale, CA, USA) for high-risk HPV testing detects HPV E6 and E7 DNA via real-time PCR in a mobile system of easy execution requiring minimal manual intervention. The system provides results in about 1 h. The hr- HPV prevalence data, overall and partial genotyping, were analyzed considering the following age groups: 20-34, 35-44, and 45-65 years old.
FINDINGS
RESULTS
2168 women were enrolled: 614 (28.3%) in La Paz, 743 (34.3%) in Toro Toro, and 811 (37.4%) in Acasio. Only one sample was collected from each participant. 2043 (94.2%) of 2168 samples were adequate for HPV testing. 255 (12.5%) samples were positive for high-risk HPV. Comparing the urban area (La Paz) versus rural combined areas (Acasio+Toro Toro), using a logistic model, the HPV total rate was statistically significantly higher in the city of La Paz (15.0% vs 11.4%; OR:1.37;95% CI: 1.04-1.80). Furthermore, the HPV prevalence was declining by age, and the urban/rural odds ratio was 1.50; (95% IC 1.13-19). The overall HPV 16 positivity was 2.7% (55/2043) and for HPV 18/45 was 1.8% (37/2043) without any statistically significant differences between the three BHU enrolling centers. Only the prevalence of HPV group '39/56/66/68' was significantly higher in La Paz (p<0,001) in comparison to Acasio and Toro Toro.
INTERPRETATION
CONCLUSIONS
The total and age-adjusted prevalence of high-risk HPV infection in rural and urban areas in Bolivia, as measured with a validated test for screening, is similar to that observed in Europe and the USA. Our study shows that a screening protocol for HPV testing with self-sampling would be feasible in urban and rural areas in Bolivia, and that the reported high occurrence of cervical cancer in Bolivia is not related to a higher rate of high-risk HPV infections. Carrying out HPV tests locally avoids the issues associated with transportation and storage of the collected material and allows the participant to wait in the clinic for the test result, overcoming the very long response time for screening test in Bolivia.
Identifiants
pubmed: 38451956
doi: 10.1371/journal.pone.0292605
pii: PONE-D-22-15658
pmc: PMC10919649
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0292605Informations de copyright
Copyright: © 2024 Carozzi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMJ. 2018 Dec 5;363:k4823
pubmed: 30518635
Int J Cancer. 2018 Aug 15;143(4):861-868
pubmed: 29569715
Prev Med. 2020 Jun;135:106076
pubmed: 32247010
IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636
pubmed: 18354839
Br J Cancer. 2015 Feb 17;112(4):667-75
pubmed: 25633037
PLoS One. 2022 Jul 29;17(7):e0272205
pubmed: 35905130
Int J Cancer. 2016 Jul 15;139(2):281-90
pubmed: 26850941
Int J Womens Health. 2020 Dec 16;12:1197-1204
pubmed: 33364853
Clin Microbiol Infect. 2021 Aug;27(8):1083-1095
pubmed: 33975008
J Low Genit Tract Dis. 2020 Jan;24(1):1-13
pubmed: 31714325
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
BMC Infect Dis. 2020 Mar 6;20(1):204
pubmed: 32143643
BMC Public Health. 2014 Jun 12;14:596
pubmed: 24927941
J Natl Cancer Inst. 2012 Feb 8;104(3):166-7
pubmed: 22271766
J Natl Cancer Inst. 2014 Dec 05;107(1):400
pubmed: 25479804
J Clin Microbiol. 2015 Jan;53(1):52-9
pubmed: 25339396
Ecancermedicalscience. 2020 Nov 10;14:1138
pubmed: 33281930
Asian Pac J Cancer Prev. 2001 Apr-Jun;2(2):135-141
pubmed: 12718645
J Natl Cancer Inst. 2014 Sep 13;106(10):
pubmed: 25217779
BMJ Open. 2016 Aug 04;6(8):e011022
pubmed: 27491667
Clin Microbiol Infect. 2015 Sep;21(9):817-26
pubmed: 25936581
Sex Health. 2015 Aug;12(4):279-86
pubmed: 26028338
S Afr Med J. 2018 Dec 13;109(1):47-52
pubmed: 30606304
Cancer Prev Res (Phila). 2019 Mar;12(3):159-170
pubmed: 30651294
J Natl Cancer Inst. 2005 Jun 15;97(12):938-9; author reply 939-41
pubmed: 15956659
Ann Glob Health. 2014 Sep-Oct;80(5):412-7
pubmed: 25512156
J Clin Virol. 2014 May;60(1):44-9
pubmed: 24630483
Cancer Causes Control. 2003 Aug;14(6):505-12
pubmed: 12948281
Lancet Oncol. 2019 Feb;20(2):229-238
pubmed: 30658933
Int J Clin Oncol. 2015 Oct;20(5):974-81
pubmed: 25652908
Cytopathology. 2021 Nov;32(6):712-713
pubmed: 34161630
Vaccine. 2008 Aug 19;26 Suppl 10:K29-41
pubmed: 18847555